Trillium Health Resources Pharmacy Prior Approval Request for



Immunomodulators: Cimzia

Member Information				
1. Member Last Name:	:2. First Name:		5. Member Gender:	
3. Member ID #:				
Prescriber Information				
6. Prescribing Provider NPI #:				
			Ext	
Drug Information				
8. Drug Name:	9. Strength	:	10. Quantity Per 30 Days:	
			Days 🗌 180 Days 🔲 365 Days 🗀	
Clinical Information				
4. Has the member been tested	egnosis of Ankylosing Spondy er injectable biologic immun- dered and screened for the p d with Hep B SAG and Core A d inadequate symptom relie- eive treatment with NSAIDS cal evidence of severe or rap and failure of Cosentyx, Enbr	omodulator? \(\text{Yes} \) bresence of latent tube b? \(\text{Yes} \) from treatment with due to contraindication idly progressing disea	at least two NSAIDS? Yes No ons? Yes No se	
4. Has the member been tested	gnosis of moderate to sever er injectable biologic immun dered and screened for the p d with Hep B SAG and Core A	omodulator? Yes resence of latent tub b? Yes No		
Request for Plaque Psoriasis (A	Adult)			
1. Does the member have a do	cumented definitive diagnos	is of moderate-to-sev	ere Chronic Plaque Psoriasis? 🗆 Yes	
2. Is the member 18 years of ag	ge or older? 🗆 Yes 🗆 No			
3. Is the member not on anoth 4. Has the member been considered to the consideration of the	-		No erculosis infection (not required for	
5. Has the member been tested	d with Hep B SAG and Core A	b? □ Yes □ No		
6. Does the member have a bo	dy surface area (BSA) involve	ement of at least 3%?	□ Yes □ No	

Trillium Health Resources Pharmacy Prior Approval Request for



7. Does the member have involvement of the palms, soles, head and neck, or genitalia, causing disruption in normal daily activities and/or employment? Yes No No No No No Yes No No Yes No
Request for Psoriatic Arthritis 1. Does the member have a documented definitive diagnosis of Psoriatic Arthritis? ☐ Yes ☐ No
2. Is the member 18 years of age or older (OR 2 years or older for Simponi Aria)? ☐ Yes ☐ No
3. Is the member not on another injectable biologic immunomodulator? ☐ Yes ☐ No
4. Has the member been considered and screened for the presence of latent tuberculosis infection (not required for Otezla? ☐ Yes ☐ No
5. Has the member been tested with Hep B SAG and Core Ab (not required for Otezla? Yes No
6. Does the member have a documented inadequate response or inability to take methotrexate? \square Yes \square No
7. Has the member had a trial and failure of Cosentyx, Enbrel or Humira or a clinical reason member cannot try Cosentyx, Enbrel or Humira? Yes No
Cosentyx, Entire of Humina: 🗆 Tes 🗆 No
Request for Rheumatoid Arthritis
1. Does the member have a diagnosis of Rheumatoid Arthritis? Yes No
2. Is the member not an another injectable biologic immunemedulator? \Box Vec \Box No.
2. Is the member not on another injectable biologic immunomodulator? ☐ Yes ☐ No 3. Has the member been considered and screened for the presence of latent tuberculosis? ☐ Yes ☐ No
 2. Is the member not on another injectable biologic immunomodulator? ☐ Yes ☐ No 3. Has the member been considered and screened for the presence of latent tuberculosis? ☐ Yes ☐ No 4. Has the member been tested with Hep B SAG and Core Ab? ☐ Yes ☐ No
 3. Has the member been considered and screened for the presence of latent tuberculosis? ☐ Yes ☐ No 4. Has the member been tested with Hep B SAG and Core Ab? ☐ Yes ☐ No 5. Has the member experienced a therapeutic failure/inadequate response with methotrexate or at least one disease
3. Has the member been considered and screened for the presence of latent tuberculosis? ☐ Yes ☐ No 4. Has the member been tested with Hep B SAG and Core Ab? ☐ Yes ☐ No 5. Has the member experienced a therapeutic failure/inadequate response with methotrexate or at least one disease modifying antirheumatic drug (e.g. leflunomide, hydroxychloroquine, minocycline, sulfasalazine)? ☐ Yes ☐ No
 3. Has the member been considered and screened for the presence of latent tuberculosis? ☐ Yes ☐ No 4. Has the member been tested with Hep B SAG and Core Ab? ☐ Yes ☐ No 5. Has the member experienced a therapeutic failure/inadequate response with methotrexate or at least one disease
3. Has the member been considered and screened for the presence of latent tuberculosis? ☐ Yes ☐ No 4. Has the member been tested with Hep B SAG and Core Ab? ☐ Yes ☐ No 5. Has the member experienced a therapeutic failure/inadequate response with methotrexate or at least one disease modifying antirheumatic drug (e.g. leflunomide, hydroxychloroquine, minocycline, sulfasalazine)? ☐ Yes ☐ No 6. Is the member unable to receive methotrexate or disease modifying antirheumatic drug due to contraindications or intolerabilities? ☐ Yes ☐ No 7. Does the member have clinical evidence of severe or rapidly progressing disease? ☐ Yes ☐ No
3. Has the member been considered and screened for the presence of latent tuberculosis? ☐ Yes ☐ No 4. Has the member been tested with Hep B SAG and Core Ab? ☐ Yes ☐ No 5. Has the member experienced a therapeutic failure/inadequate response with methotrexate or at least one disease modifying antirheumatic drug (e.g. leflunomide, hydroxychloroquine, minocycline, sulfasalazine)? ☐ Yes ☐ No 6. Is the member unable to receive methotrexate or disease modifying antirheumatic drug due to contraindications or intolerabilities? ☐ Yes ☐ No 7. Does the member have clinical evidence of severe or rapidly progressing disease? ☐ Yes ☐ No 8. Has the member had a trial and failure of Enbrel or Humira or a clinical reason member cannot try Enbrel or
3. Has the member been considered and screened for the presence of latent tuberculosis? ☐ Yes ☐ No 4. Has the member been tested with Hep B SAG and Core Ab? ☐ Yes ☐ No 5. Has the member experienced a therapeutic failure/inadequate response with methotrexate or at least one disease modifying antirheumatic drug (e.g. leflunomide, hydroxychloroquine, minocycline, sulfasalazine)? ☐ Yes ☐ No 6. Is the member unable to receive methotrexate or disease modifying antirheumatic drug due to contraindications or intolerabilities? ☐ Yes ☐ No 7. Does the member have clinical evidence of severe or rapidly progressing disease? ☐ Yes ☐ No
3. Has the member been considered and screened for the presence of latent tuberculosis? ☐ Yes ☐ No 4. Has the member been tested with Hep B SAG and Core Ab? ☐ Yes ☐ No 5. Has the member experienced a therapeutic failure/inadequate response with methotrexate or at least one disease modifying antirheumatic drug (e.g. leflunomide, hydroxychloroquine, minocycline, sulfasalazine)? ☐ Yes ☐ No 6. Is the member unable to receive methotrexate or disease modifying antirheumatic drug due to contraindications or intolerabilities? ☐ Yes ☐ No 7. Does the member have clinical evidence of severe or rapidly progressing disease? ☐ Yes ☐ No 8. Has the member had a trial and failure of Enbrel or Humira or a clinical reason member cannot try Enbrel or
3. Has the member been considered and screened for the presence of latent tuberculosis? Yes No
3. Has the member been considered and screened for the presence of latent tuberculosis? Yes No No Has the member been tested with Hep B SAG and Core Ab? Yes No No In the member experienced a therapeutic failure/inadequate response with methotrexate or at least one disease modifying antirheumatic drug (e.g. leflunomide, hydroxychloroquine, minocycline, sulfasalazine)? Yes No In the member unable to receive methotrexate or disease modifying antirheumatic drug due to contraindications or intolerabilities? Yes No Does the member have clinical evidence of severe or rapidly progressing disease? Yes No Has the member had a trial and failure of Enbrel or Humira or a clinical reason member cannot try Enbrel or Humira? No Request for Non-Radiographic Axial Spondyloarthritis
3. Has the member been considered and screened for the presence of latent tuberculosis? \(\text{ Yes } \) No 4. Has the member been tested with Hep B SAG and Core Ab? \(\text{ Yes } \) No 5. Has the member experienced a therapeutic failure/inadequate response with methotrexate or at least one disease modifying antirheumatic drug (e.g. leflunomide, hydroxychloroquine, minocycline, sulfasalazine)? \(\text{ Yes } \) No 6. Is the member unable to receive methotrexate or disease modifying antirheumatic drug due to contraindications or intolerabilities? \(\text{ Yes } \) No 7. Does the member have clinical evidence of severe or rapidly progressing disease? \(\text{ Yes } \) No 8. Has the member had a trial and failure of Enbrel or Humira or a clinical reason member cannot try Enbrel or Humira? \(\text{ Yes } \) No Request for Non-Radiographic Axial Spondyloarthritis 1. Does the member have a diagnosis of Non-Radiographic Axial Spondyloarthritis? \(\text{ Yes } \) No
3. Has the member been considered and screened for the presence of latent tuberculosis? Yes No No Has the member been tested with Hep B SAG and Core Ab? Yes No No In the member experienced a therapeutic failure/inadequate response with methotrexate or at least one disease modifying antirheumatic drug (e.g. leflunomide, hydroxychloroquine, minocycline, sulfasalazine)? Yes No In the member unable to receive methotrexate or disease modifying antirheumatic drug due to contraindications or intolerabilities? Yes No Does the member have clinical evidence of severe or rapidly progressing disease? Yes No Has the member had a trial and failure of Enbrel or Humira or a clinical reason member cannot try Enbrel or Humira? No Request for Non-Radiographic Axial Spondyloarthritis
3. Has the member been considered and screened for the presence of latent tuberculosis? \(\) Yes \(\) No 4. Has the member been tested with Hep B SAG and Core Ab? \(\) Yes \(\) No 5. Has the member experienced a therapeutic failure/inadequate response with methotrexate or at least one disease modifying antirheumatic drug (e.g. leflunomide, hydroxychloroquine, minocycline, sulfasalazine)? \(\) Yes \(\) No 6. Is the member unable to receive methotrexate or disease modifying antirheumatic drug due to contraindications or intolerabilities? \(\) Yes \(\) No 7. Does the member have clinical evidence of severe or rapidly progressing disease? \(\) Yes \(\) No 8. Has the member had a trial and failure of Enbrel or Humira or a clinical reason member cannot try Enbrel or Humira? \(\) Yes \(\) No Request for Non-Radiographic Axial Spondyloarthritis 1. Does the member have a diagnosis of Non-Radiographic Axial Spondyloarthritis? \(\) Yes \(\) No 2. Is the member not on another injectable biologic immunomodulator? \(\) Yes \(\) No 3. Has the member failed an adequate trial of a Non-Steroidal Anti-Inflammatory Drug (NSAID) unless contraindicated? \(\) Yes \(\) No
3. Has the member been considered and screened for the presence of latent tuberculosis? \ Yes \ No 4. Has the member been tested with Hep B SAG and Core Ab? \ Yes \ No 5. Has the member experienced a therapeutic failure/inadequate response with methotrexate or at least one disease modifying antirheumatic drug (e.g. leflunomide, hydroxychloroquine, minocycline, sulfasalazine)? \ Yes \ No 6. Is the member unable to receive methotrexate or disease modifying antirheumatic drug due to contraindications or intolerabilities? \ Yes \ No 7. Does the member have clinical evidence of severe or rapidly progressing disease? \ Yes \ No 8. Has the member had a trial and failure of Enbrel or Humira or a clinical reason member cannot try Enbrel or Humira? \ Yes \ No Request for Non-Radiographic Axial Spondyloarthritis 1. Does the member have a diagnosis of Non-Radiographic Axial Spondyloarthritis? \ Yes \ No 2. Is the member not on another injectable biologic immunomodulator? \ Yes \ No 3. Has the member failed an adequate trial of a Non-Steroidal Anti-Inflammatory Drug (NSAID) unless contraindicated? \ Yes \ No 4. Has the member been considered and screened for the presence of latent tuberculosis? \ Yes \ No
3. Has the member been considered and screened for the presence of latent tuberculosis? \(\) Yes \(\) No 4. Has the member been tested with Hep B SAG and Core Ab? \(\) Yes \(\) No 5. Has the member experienced a therapeutic failure/inadequate response with methotrexate or at least one disease modifying antirheumatic drug (e.g. leflunomide, hydroxychloroquine, minocycline, sulfasalazine)? \(\) Yes \(\) No 6. Is the member unable to receive methotrexate or disease modifying antirheumatic drug due to contraindications or intolerabilities? \(\) Yes \(\) No 7. Does the member have clinical evidence of severe or rapidly progressing disease? \(\) Yes \(\) No 8. Has the member had a trial and failure of Enbrel or Humira or a clinical reason member cannot try Enbrel or Humira? \(\) Yes \(\) No Request for Non-Radiographic Axial Spondyloarthritis 1. Does the member have a diagnosis of Non-Radiographic Axial Spondyloarthritis? \(\) Yes \(\) No 2. Is the member not on another injectable biologic immunomodulator? \(\) Yes \(\) No 3. Has the member failed an adequate trial of a Non-Steroidal Anti-Inflammatory Drug (NSAID) unless contraindicated? \(\) Yes \(\) No

Trillium Health Resources Pharmacy Prior Approval Request for



Signature of Prescriber:	Date:			
(Prescriber Signature Mandatory)				
I certify that the information provided is accurate and complete to the best of my knowledge, and I understand that				
any falsification, omission, or concealment of material	fact may subject me to civil or criminal liability.			